Mettler-Toledo International Inc. — Q1 2018 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2018, compared with Q1 2017. Mettler-Toledo supplies precision instruments and related services across laboratory, industrial, and food-retailing markets. Amounts below are in U.S. dollars.
Financial and operating results
- Revenue: $660.8 million, up 11% reported and 5% in local currencies. Biotix contributed approximately 1.5 percentage points to local-currency growth. Product sales were $510.9 million; service revenue was $149.9 million.
- Profitability: Gross profit was $374.9 million, with a 56.7% gross margin versus 57.8% a year earlier. Earnings before taxes were $117.4 million versus $113.8 million; net earnings were $93.3 million versus $92.5 million. Diluted EPS was $3.58 versus $3.48.
- Costs and margins: Cost of sales increased to 43.3% of sales from 42.2%. SG&A declined to 30.4% of sales from 31.2%; R&D remained 5.3%. Restructuring charges rose to $4.4 million from $1.4 million.
- Cash flow and investment: Operating cash flow was $76.6 million, up from $67.6 million. Capital expenditures were $29.8 million versus $21.0 million, resulting in net cash used in investing activities of $22.5 million. Share repurchases were $118.8 million.
- Liquidity and debt: Cash and equivalents were $98.9 million, down from $148.7 million at year-end. Total debt was $993.6 million, including $14.9 million current and $978.7 million long-term debt. $319.7 million remained available under the $800 million credit agreement. Current assets were $927.4 million and current liabilities $636.9 million.
- Other metrics: Total comprehensive income was $122.2 million versus $116.3 million. Segment profit increased to $139.5 million from $126.5 million.
Changes and management commentary
- Laboratory-related sales, about 52% of revenue, rose 10% in local currencies; industrial-related sales, about 40%, declined 1%; food-retailing sales, about 8%, were flat in local currencies.
- Chinese Operations had the strongest reported segment growth: external sales increased 25% and segment profit 33%. U.S. segment profit fell 12%, while Western European segment profit fell 26%; Swiss segment profit rose 28%.
- Management attributed the lower gross margin mainly to currency translation, unfavorable mix, and initial costs at new manufacturing facilities, partly offset by pricing. SG&A benefited from lower cash incentive expense and cost savings, alongside continued sales and growth investments.
- Management described global market conditions as generally favorable, but cautioned about economic uncertainty, difficult comparisons during 2018, and potential volatility in China. It expects operating cash flow, credit-facility availability, and local facilities to cover anticipated working-capital and capital-spending needs for the foreseeable future. No specific full-year revenue or EPS guidance is provided in the filing text.
- The company expects $30–$40 million of net investment in new or expanded manufacturing facilities over the next two years and continues to explore acquisitions. In April 2018, non-U.S. pension plans lent a subsidiary $39.6 million, used to repay credit-facility borrowings.
Risks, contingencies, and unusual items
- Foreign-exchange exposure is material: management estimates a 1% strengthening of the Swiss franc against the euro would reduce annual pretax earnings by approximately $1.6–$1.8 million; a 1% weakening of the Chinese renminbi against the U.S. dollar would reduce them by approximately $1.0–$1.3 million.
- The company recorded a provisional $72 million transition-tax charge in 2017, of which $59 million is expected to be paid over up to eight years. Tax accounting remained subject to completion and could be adjusted during 2018.
- Q1 restructuring charges were $4.4 million, primarily employee-related. Prior-year other income included a one-time $3.4 million gain on a Swiss facility sale, affecting the comparison.
- Management said routine legal and environmental proceedings were not expected to have a material adverse effect. The filing reports no material change to previously disclosed risk factors or market-risk disclosures.
Key facts for investors to verify
- Whether local-currency growth and margin trends persist as the company faces tougher comparisons, especially in China and industrial markets.
- How much of reported growth and segment performance reflects currency movements, Biotix, and other acquisition effects.
- Cash conversion and the pace of capital spending, buybacks, and debt changes; cash declined by $49.7 million during the quarter.
- Potential changes to the provisional Tax Act accounting and the expected timing of transition-tax payments.
- Progress and costs at new manufacturing facilities, restructuring actions, and the impact of foreign-exchange movements on earnings and debt.